HBSP (USA)
-
Building an Integrated Biopharma Company: Crucell (A)
Hamermesh, Richard G.; Van Der Steen, Marianne; Harmeling, Susan S.Case HBS-815085-EEntrepreneurshipBy 2009, Crucell had become the largest biopharma company in the Netherlands and a symbol of national pride. The case traces the evolution of the company from a University spin-off into a fully-integrated company. Crucell's success, particularly in the vaccine space, had begun to attract the attention of much larger pharmaceutical companies. While there was much appeal to working with these companies, these relationships could also challenge Cruc...Starting at €8.20
-
El Reinado de Messier en Vivendi Universal
Khurana, Rakesh; Beyersdorfer, Daniela; Dessain, VincentCase HBS-412S03Leadership and People ManagementSe centra en una crisis en la junta de Vivendi. Destaca las dificultades que surgen cuando la presión dramática desde fuera la sala de juntas afecta la dinámica sala de juntas. En este caso, hay dos eventos. El primero es un inesperado gran pérdida financiera y una crisis de liquidez en espera de que los directores de las fuerzas de Vivendi para hacer frente a la cuestión de despedir a su CEO. Cualquier cosa que ellos decidan, sus acciones serán ...Starting at €8.20
-
Building an Integrated Biopharma Company: Crucell (B)
Hamermesh, Richard G.; Van Der Steen, Marianne; Harmeling, Susan S.Case HBS-815086-EEntrepreneurshipThe Crucell (B) case updates events at Crucell since 2009. In September, 2009, Johnson & Johnson acquired 18% of Crucell for $400 million. This investment was part of a business development deal. Subsequently, in 2012, Johnson & Johnson acquired Crucell for $2.8 billion.Starting at €5.74